Private equity firm Summit Partners has divested its stake in Dreampath Diagnostics, a company specializing in automated workflow systems for anatomical pathology labs. The buyer is Halma, a London-listed global group focused on life sciences, diagnostics, and engineering.

Dreampath, which manages over 300 million tissue samples globally, provides systems that assist pathology labs in tracking and retrieving these critical samples. The company currently serves more than 500 labs across 50 countries.

Summit Partners initially invested in Dreampath in July 2025 as part of a growth capital round. Since then, Dreampath has broadened its product and service offerings. The exit marks a successful realization for Summit Partners, highlighting investor appetite for specialized diagnostics technology providers.

The acquisition by Halma signals a consolidation trend within the diagnostics sector, particularly for companies offering workflow efficiency solutions. Investors should monitor how Halma integrates Dreampath's operations to drive further growth and market penetration.